Login / Signup

Targeting Breast Cancer Using 177 Lu-Labeled Trastuzumab and Trastuzumab Fragment : First-in-Human Clinical Experience.

Yogesh RathoreTamanna LakhanpalSudipta ChakrabortyRubel ChakravartyB R MittalR N Santhosh IrrinkiIshita LaroiyaKomalpreet KaurJaya Shukla
Published in: Clinical nuclear medicine (2024)
177 Lu-DOTAGA-Fab and trastuzumab are suitable for targeting the HER2 receptors.
Keyphrases
  • epidermal growth factor receptor
  • metastatic breast cancer
  • endothelial cells
  • cancer therapy
  • tyrosine kinase
  • pet imaging
  • drug delivery
  • computed tomography
  • young adults
  • breast cancer risk